AcelRx Pharmaceuticals, Inc. (ACRX) financial statements (2020 and earlier)

Company profile

Business Address 351 GALVESTON DRIVE
REDWOOD CITY, CA 94063
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments66106608011375104
Cash and cash equivalents158853801086088
Short-term investments51188 61515
Receivables10263  
Inventory, net of allowances, customer advances and progress billings31120 
Inventory31120  
Other undisclosed current assets2101211
Total current assets:72108638911976105
Noncurrent Assets
Operating lease, right-of-use asset4
Nontrade receivables00    
Property, plant and equipment151111119105
Restricted cash and investments 000000
Other noncurrent assets110    
Deferred tax assets, net 1    
Other undisclosed noncurrent assets   0000
Total noncurrent assets:201312119105
TOTAL ASSETS:911217610012886110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7756666
Accounts payable2212222
Accrued liabilities6545444
Deferred revenue0
Debt698357 
Deferred revenue and credits00311
Other undisclosed current liabilities01110  
Total current liabilities:1416141013147
Noncurrent Liabilities
Long-term debt and lease obligation2431119161814
Long-term debt, excluding current maturities2131119161814
Operating lease, liability4
Liabilities, other than long-term debt4044122
Deferred revenue and credits44122
Deferred revenue3
Deferred rent credit 0
Other liabilities0      
Other undisclosed noncurrent liabilities9197837365613
Total noncurrent liabilities:1191009895822630
Total liabilities:133116112105954037
Stockholders' equity
Stockholders' equity attributable to parent, including:(41)4(37)(5)334773
Common stock0000000
Additional paid in capital357349261241236225219
Accumulated other comprehensive income (loss)   0(0)(0)0
Accumulated deficit(398)(345)(298)(246)(203)(179)(145)
Warrants and rights outstanding     613
Other undisclosed stockholders' equity attributable to parent     (6)(13)
Total stockholders' equity:(41)4(37)(5)334773
TOTAL LIABILITIES AND EQUITY:911217610012886110

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues2281719530
Revenue, net1114 8
Sublease income1
Cost of revenue
(Cost of Goods and Services Sold)
(7)(4)(0)(12)(2)  
Gross profit:(5)(2)8517530
Operating expenses(50)(38)(47)(49)(39)(43)(36)
Other undisclosed operating income 40122  
Operating loss:(54)(36)(39)(32)(20)(38)(7)
Nonoperating income (expense)1(11)(14)(11)(4)7(15)
Investment income, nonoperating21112  
Interest and debt expense(3)(2)(3)(3)(3)(3)(3)
Other undisclosed income from continuing operations before equity method investments, income taxes   33  
Loss from continuing operations before equity method investments, income taxes:(56)(49)(56)(43)(24)(33)(25)
Other undisclosed income (loss) from continuing operations before income taxes323  (4)18
Loss from continuing operations before income taxes:(53)(47)(52)(43)(24)(38)(7)
Income tax expense (benefit)(0)(0)10(1)  
Net loss:(53)(47)(52)(43)(24)(38)(7)
Other undisclosed net income (loss) attributable to parent     4(17)
Net loss available to common stockholders, basic:(53)(47)(52)(43)(24)(33)(23)
Other undisclosed net loss available to common stockholders, diluted    (2)(7) 
Net loss available to common stockholders, diluted:(53)(47)(52)(43)(27)(40)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(53)(47)(52)(43)(24)(38)(7)
Comprehensive loss:(53)(47)(52)(43)(24)(38)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (0)004(17)
Comprehensive loss, net of tax, attributable to parent:(53)(47)(52)(43)(24)(33)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: